Search results for: 'Complex Drug'

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The application of Generative AI (Gen AI) in healthcare is a rapidly growing field. In recent years, emerging applications in drug discovery and development, medical imaging analysis, digital twins, synthetic data, and electronic health records management, and virtual assistants have garnered significant interest thanks to their potential to revolu...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

Amid shifting industry dynamics being driven by decentralization, digitalization, decarbonization and the rise of new business models, the keystone market of industrial automation, lifecycle services, is expected to experience a phase of strong short-term growth. Frost & Sullivans market analysis estimates the market size to grow from $49.56B to $6...

This project provides an overview of the effects of generative AI (Gen AI) on the healthcare and life science industry and numerous growth opportunities, including how it could overcome regulatory and cybersecurity obstacles, address the build-borrow-buy conundrum, and impact the value chain of pharmaceutical companies, medical device developers, p...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can incr...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...